Amgen acquires Filgrastim franchise rights from Roche In 100 markets
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche ("Roche") to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1, 2014. Roche has held the rights to filgrastim and pegfilgrastim under license from Kirin-Amgen, Inc. (a joint venture between Amgen and Kirin Holdings Co. Limited, of Japan) in Eastern Europe, Latin America, Asia, the Middle East and Africa since 1989.
GSK and Genmab announce submission to US regulatory authorities for Arzerra® (ofatumumab)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) and Genmab A/S (OMX: GEN) have announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for the use of Arzerra® (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy.
Roche posts strong sales growth in the first nine months of 2013
- Details
- Category: Roche
Group sales rose 6% to 34.9 billion Swiss francs in the first nine months of the year due to strong demand for Roche's HER2 breast-cancer treatments, as well as higher sales of Avastin and clinical laboratory products from the Diagnostics Division. For the fifth consecutive year Roche was ranked as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry in the Dow Jones Sustainability Index (DJSI), highlighting the Group's commitment to responsible business practices and the creation of long-term value.
Abbott reports third-quarter 2013 results
- Details
- Category: Abbott
Abbott today announced financial results for the third quarter ended Sept. 30, 2013. Third-quarter 2013 worldwide sales of $5.4 billion increased 4.3 percent on an operational basis, with strong performance in Diagnostics and Medical Devices. The sales disruption in International Nutrition is estimated to have reduced Abbott's total worldwide sales growth by nearly 2 percentage points.
AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
- Details
- Category: AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate technology for use in oncology. MedImmune has also entered into a collaboration agreement with ADC Therapeutics to jointly develop two of ADC Therapeutics' antibody-drug conjugate programmes in preclinical development.
AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into an agreement with Janssen Pharmaceuticals K. K. in Japan to co-promote abiraterone acetate, an innovative oral therapy for the treatment of patients with prostate cancer. Currently the main treatment option available to patients in Japan is medical castration, however prostate cancer can still progress in many patients because androgens are produced in other tissues.
Novartis launches fully interactive Facebook ‘Retina App’ on World Sight Day to raise awareness of retinal disease
- Details
- Category: Novartis
Today, Novartis further embraces the worldwide vision impairment community by supporting World Sight Day with the launch of a new Facebook 'Retina App'. The app simulates retinal disease by illustrating the user's journey by showing a highly realistic view of what the impact of vision loss on their daily life could look like.
More Pharma News ...
- Roche inaugurates Translational and Clinical Research Center at the Alexandria Center for Life Science in New York City
- Bayer accelerates clinical development of promising new drug candidates
- Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin
- Secukinumab (AIN457) showed superiority over Enbrel®
- International Atherosclerosis Society and Pfizer Independent Grants for Learning & Change collaborate on new grant opportunity
- Amgen successfully completes Onyx Pharmaceuticals tender offer
- Takeda and Lundbeck announce FDA approval of Brintellix™ (vortioxetine)